Dipharma appoints a new CEO, Xellia gets a new commercial head in North America, promotions are made at Lek, GVK Bio and the APhA, while appointments are seen at Auris Medical and Tris Pharma.

Takeda tantalizingly disclosed during its third quarter results that it has set aside funds for an acquisition worth around $450m in an undisclosed emerging market. What are the likely targets?

Micro Therapeutic Research Labs is now under the scanner over alleged data integrity concerns. European Medicines Agency (EMA) is evaluating medicines based on studies done by the Indian firm.

Three more Indian pharmaceutical players have been pulled up by overseas regulators over data integrity issues in another blow to the reputation of the flagship industry.